Cenicriviroc, which is a dual antagonist of CCR5 and CCR2, has been found to be effective in slowing the progression of non-alcoholic fatty liver disease [51] and reducing liver damage in rodents with cholestasis [52]. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatotic liver disease.